• Publications
  • Influence
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
TLDR
S-1 is non-inferior to fluorouracil and, in view of the convenience of an oral administration, could replace intravenous fluoroursacil for treatment of unresectable or recurrent gastric cancer, at least in Asia. Expand
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
TLDR
The English version of the JSCCR Guidelines 2014 can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient, and can, therefore, be used for treating colorectal cancer in clinical practice. Expand
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a
TLDR
In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer. Expand
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus.
TLDR
Despite its significant toxicity, this combined modality seemed to have curative potential even in cases of locally advanced carcinoma of the esophagus. Expand
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical
TLDR
Neither investigational regimen, FP nor UFTM, showed a survival advantage as compared with FU alone, althoughFP will remain a reference arm in a future trial for advanced gastric cancer. Expand
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
TLDR
Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer. Expand
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
TLDR
The English version of the JSCCR Guidelines 2016 is presented, which can be used as a tool for treating colorectal cancer in actual clinical practice settings and as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. Expand
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
TLDR
Definitive CRT for SCC of the esophagus is effective with substantial toxicities, and additional investigation to minimize the normal tissue toxicities is warranted. Expand
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system
TLDR
A randomized controlled trial is required to establish the appropriate chemotherapy regimen for advanced NEC of the digestive system and HBP primary sites and elevated lactate dehydrogenase levels are unfavorable prognostic factors for survival. Expand
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
TLDR
This regimen is considered to be active against AGC with acceptable toxicity, and the maximum-tolerated dose, recommended dose, dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gastric cancer (AGC). Expand
...
1
2
3
4
5
...